IRCT20230801058996N2招募中1 期
Safety and efficacy of allogeneic natural killer cells therapy in acute myeloid leukemia (other than M3) patients transplanted with allogeneic hematopoietic stem cell
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 years 至 80 years（—）
- 性别
- All
入选标准
- •Patients with acute myeloid leukemia (other than M3) confirmed by peripheral blood and bone marrow morphology, and flow cytometry and molecular assessments
- •History of transplantation with compatible allogeneic hematopoietic stem cells
- •Kanofsky index above 70%
- •Expected survival of more than six months
- •Absence of other confirmed malignancies
- •Entering the second complete remission phase (recovery of patients after the first recurrence)
- •High risk-patients with negative or positive minimal residual disease
排除标准
- •Patients with acute myeloid leukemia-M3
- •Central nervous system involvement with leukemic cells in the last 3 months
研究者
相似试验
招募中
1 期
Allogeneic natural killer cell therapy in multiple myeloma patientsMultiple myelomaIRCT20230801058996N1Shahid Beheshti University of Medical Sciences15
招募中
1 期
Effect of NK cell therapy in COVID-19IRCT20200417047113N1Middle East Gene Therapy corporation70
招募中
1 期
Application of Cord Blood Platelet Gel (CBPG) for the treatment of non-healing skin ulcers due to the cutaneous chronic GVHDIRCT20190101042197N1Royan Stem cell Technology Co.15
招募中
1 期
atural Killer cell in acute myeloid leukemiaAcute myeloblastic leukemiaacute myeloid leukemia.C92.0IRCT20140818018842N35Tehran University of Medical Sciences10
招募中
2 期
Effect of treatmen with natural killer cells in acute myeloid leukemiaAcute myeloblastic leukemiaAcute Myeloid leukemia.C92.0IRCT20200417047113N2Middle East Gene Therapy corporation5